



Press Release

## **Mymetics announces successful preclinical results with malaria transmission-blocking vaccine candidate**

**Epalinges, Switzerland, 5 April 2016** – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines to prevent transmission of human infectious diseases, announced today that the preclinical study with Mymetics' virosome based formulations for a malaria transmission-blocking vaccine candidate has been successful. The study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the *Plasmodium falciparum* parasite.

In November 2014, Mymetics' virosome technology platform and its specialist virosome know-how was selected to develop an innovative malaria transmission-blocking vaccine candidate in partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

With funding from the PATH Malaria Vaccine Initiative, several virosome vaccine formulations, each incorporating two different malaria parasite proteins supplied by LMIV, were tested in animal studies and compared to other malaria transmission-blocking vaccine constructs.

Mymetics has shown separately in 2011 in a privately funded Phase 1b clinical trial in Tanzania that a virosome based vaccine for *Plasmodium falciparum* could reduce malaria episodes in children by more than 50%.<sup>1</sup>

The company is currently evaluating opportunities for supporting the next steps of development.

According to the World Health Organization, in 2015, 97 countries had ongoing malaria transmission. There were an estimated 214 million new cases of malaria in 2015 and an estimated 438 000 deaths.

### **Malaria transmission-blocking vaccine candidates**

Transmission-blocking vaccine candidates seek to interrupt the life cycle of the parasite by inducing antibodies that prevent the parasite from maturing in the mosquito after it takes a blood meal from a vaccinated person.

### **About NIAID**

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses.

### **About Mymetics**

Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. It currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Herpes Simplex Virus and the RSV vaccine.

Mymetics' core technology and expertise are in the use of virosomes, which are virus like particles containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics' vaccines are designed to induce protection against early



transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.

**CONTACTS:**

**Mymetics Corporation**

Ronald Kempers

CEO

Tel: +41 21 653 4535

**Media:**

Christophe Lamps

Senior Partner

Dynamics Group

Mobile: + 41 79 476 26 87

Email: [cla@dynamicsgroup.ch](mailto:cla@dynamicsgroup.ch)

**Media US:**

Michelle Linn

Linnden Communications

Phone: +1 774 696 38 03

[linnmich@comcast.net](mailto:linnmich@comcast.net)

**Forward looking statements**

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.

---

<sup>i</sup> Plos One, 6: e22273, 2011